– UK, Oxford – Oxford Nanopore Technologies plc (LON: ONT), the company delivering a new generation of nanopore-based molecular sensing technology, today announced the appointment of Kate Priestman to its Board as a Non-Executive Director effective from 13 July 2023, to bring extensive experience as a biopharma executive for more than 25 years, serving in leadership roles across commercial, operations, corporate strategy, communications, and government affairs.
“We are extremely pleased to welcome Kate as a Non-Executive Director of Oxford Nanopore. Kate’s impressive track-record of working with a UK-headquartered, global leader in biopharma, along with her other extensive experience, uniquely positions her to understand and support the next phase of growth for Oxford Nanopore. Kate understands this opportunity better than most, and we look forward to working with her as Oxford Nanopore starts to expand beyond life science research into additional clinical and applied markets.” said Board Chair, Duncan Tatton-Brown.
About Kate Priestman
Kate Priestman was most recently SVP of R&D Strategy, Portfolio, and Operations at GlaxoSmithKline, where she led the evolution of GSK’s science and technology strategy, portfolio management, and global R&D operations & business transformation, helping steer the FTSE 100 company’s growth. Kate also served on GSK’s separation board, delivering the successful spin-out of Haleon plc in 2022.
In addition, she previously held global and UK roles at Eli Lilly & Co and Zeneca, after an early career at the BBC, where she spent several years as a broadcaster. Kate also currently serves as a Trustee of RBG Kew, an organization with around 500 scientists working globally to understand plant biology and fight biodiversity loss.
Kate Priestman said: “I am excited to join Oxford Nanopore at this pivotal juncture in its growth journey. Oxford Nanopore has an incredible opportunity with its technology that can potentially transform sectors critical to our future. The company is expanding and maturing at pace, yet has retained its inherent creativity and innovation – a potent combination to harness as it establishes itself as a global life science superpower.
I look forward to working with the Board and the executive team to drive Oxford Nanopore’s long-term success.”
Source: https://nanoporetech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
